Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers

Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers

An exploratory analysis of the expression of MFI2-AS1 will be performed at the plasma level with the objective of comparing this expression with tumor tissue. The objective would be to be able to use long non-coding RNA as a biomarker for diagnosis before tissue analysis and for patient follow-up. In addition, correlations will be made between tumor expression of MFI2-AS1 and genetic and immune alterations in tumors in order to better clarify the link between the expression of this long non-coding RNA and the characteristics of the tumor and of the tumor. tumor microenvironment.

Inclusion Criteria:

• Adult patient
• Localized kidney tumors> T1a
• Patient having signed an informed consent
• Patient affiliated to a health insurance plan
• Subject having signed a consent form to participate in research and the constitution of a collection and genetic analyzes

Exclusion Criteria:

• Metastatic carcinoma from the outset
• Contraindication to performing a TAP CT with injection of contrast product
• Inability to provide informed information about the subject (subject in an emergency situation, difficulties in understanding, etc.)
• Subject under legal protection
• Subject under tutorship or curatorship
• Pregnancy
• Feeding with milk